MARKET

RNA

RNA

Avidity Biosciences, Inc.
NASDAQ
32.28
+0.08
+0.25%
Pre Market: 29.01 -3.27 -10.13% 04:01 05/06 EDT
OPEN
31.92
PREV CLOSE
32.20
HIGH
32.70
LOW
31.45
VOLUME
1
TURNOVER
--
52 WEEK HIGH
56.00
52 WEEK LOW
21.51
MARKET CAP
3.89B
P/E (TTM)
-11.1754
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNA last week (0428-0502)?
Weekly Report · 21h ago
RBC Capital Remains a Buy on Avidity Biosciences (RNA)
TipRanks · 3d ago
Weekly Report: what happened at RNA last week (0421-0425)?
Weekly Report · 04/28 10:47
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
NASDAQ · 04/24 21:15
Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street
The Wall Street Journal · 04/22 09:30
Gene therapy developers rise on comments from FDA's Makary
Seeking Alpha · 04/21 17:50
RBC sees Makary interview as potentially positive for biotech stocks
TipRanks · 04/21 16:20
Weekly Report: what happened at RNA last week (0414-0418)?
Weekly Report · 04/21 10:47
More
About RNA
More
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
Recently
Symbol
Price
%Change

Webull offers Avidity Biosciences Inc stock information, including NASDAQ: RNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNA stock methods without spending real money on the virtual paper trading platform.